Frontlight ResearchEarly access
WithdrawnNo phase
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients
Key facts
- Who runs it
- The University of Texas Health Science Center at San Antonio
- Where
- San Antonio, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Dec 2023
- Ended
- Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- High Intensity Interval Training
- Record updated
- 26 February 2024
- Why it stopped
- PI left the institution, no subjects were enrolled
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Diagnosis of metastatic prostate cancer; Includes metastatic hormone sensitive prostate cancer, AND; Metastatic castration resistant prostate cancer
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Planned to receive docetaxel chemotherapy for treatment of prostate cancer with plan for at least 4 cycles of therapy
- Estimated life expectancy > 6 months
- Must be receiving androgen deprivation therapy (ADT) during study period or have had prior bilateral orchiectomy
- 4 weeks from any major surgery
- Age > 18 years
- Willing to participate in exercise intervention per protocol
- Cleared by study personnel to participate in exercise intervention based on screening physical exam
- Eligible patients can be participating in other investigational protocols or consent to other investigational protocols during this study participation if it does not affect docetaxel dosing, include additional cytotoxic chemotherapy, or interfere with exercise intervention
- Patients must be able to travel to one of the study-designated exercise facilities up to three days per week
- Required Initial Laboratory Values:; Absolute neutrophil count (12) ≥ 1500/uL; Platelet count ≥ 100,000/uL; Creatinine ≤ 1.5 x upper limits of normal; Bilirubin ≤ 1.5 x upper limits of normal; Aspartate aminotransferase (AST) ≤ 1.5 x upper limits of normal; Serum testosterone ≤ 50 ng/dL
Who cannot take part
- Has already initiated first-line chemotherapy treatment course
- Receiving additional cytotoxic chemotherapy in addition to docetaxel during study participation
- Uncontrolled asthma (patient can participate if on asthma controlling medications and has access to rescue inhaler)
- Known small cell neuroendocrine cancer of the prostate
- Poorly controlled hypertension, BP >160/90 on >1 occasion during screening period
- NYHA Class II heart failure
- Serious cardiovascular event within 6 months of consent, including transient ischemic attack, cerebrovascular accident, or myocardial infarction
- Stable or unstable angina
- Active second malignancy, with exception of non-melanoma skin cancer or non-invasive bladder cancer
- Psychiatric illness, which would prevent the patient from giving informed consent or adhering to the study protocol
- Has chest pain during physical activity (patient can participate with cardiologist clearance)
- Known physical limitation that would impede participation in exercise per protocol
- Moderate-to-severe bone pain (i.e NCI common terminology criteria of adverse events grade 2-3 bone pain)
- Men already participating in vigorous aerobic exercise for more than 60 minutes per day or structured resistance exercise (>2 upper body and >2 lower body exercises) 2 or more days a week
Where in United States
- UT Health San AntonioSan Antonio, United States
About the trial
What the trial wants to find out
This study aims to examine the use of high-intensity interval training (HIIT) and resistance training on docetaxel chemotherapy tolerability and toxicity in metastatic prostate cancer.
The 2 groups in the trial
- Exercise InterventionTreatment being tested
Participants will engage in 2-3 supervised high intensity aerobic and resistance exercise sessions per week.
Treatment: High Intensity Interval Training
- ControlNo study treatment, for comparison
Participants will continue daily routine as usual and given an informational flyer on physical activity and cancer.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of a Randomized Chemo-periodized Adjuvant High-Intensity Interval Training Intervention to Improve Chemotherapy Tolerance in Men With Metastatic Prostate Cancer
- Record updated
- 26 February 2024